Casgevy access in the United Arab Emirates: the EDE named-patient pathway

Last reviewed 2026-05-12 by the Reserve Meds clinical and regulatory team. This page combines the UAE country research module with the Casgevy drug module to describe the path families actually walk.

Quick orientation

Casgevy (exagamglogene autotemcel, often shortened to exa-cel) is the world's first approved CRISPR/Cas9 gene-edited cell therapy. The US Food and Drug Administration approved it in December 2023 for sickle cell disease and in January 2024 for transfusion-dependent beta-thalassemia, in patients aged 12 years and older. The therapy is a one-time autologous treatment, not a chronic medication, and the manufacturer Vertex Pharmaceuticals ships it only to a small set of qualified Authorized Treatment Centers globally. For a UAE family weighing this option, the practical question is not the drug supply chain, it is the institutional capability chain. Reserved for you.

Why UAE patients need Casgevy via a named-patient pathway

The United Arab Emirates is one of the most active GCC markets for advanced therapy access, and Casgevy is being introduced through the Emirates Drug Establishment's pathway for advanced therapies. The Emirati Genome Programme has accelerated identification of hemoglobinopathy carriers and affected patients, and we expect the population of UAE-resident patients eligible for Casgevy to grow each year. The access gap, however, is not primarily regulatory. Even where Casgevy is registered or being introduced, only a small set of hospitals globally hold the combination of busulfan myeloablative conditioning capability, apheresis suite throughput, certified cell-therapy infusion infrastructure, and the Vertex qualification status required to actually deliver the therapy.

The UAE's cell-therapy capability is developing rapidly. Cleveland Clinic Abu Dhabi, with its M42 affiliation to the Cleveland Clinic in Ohio, has documented adult cell-therapy capability in oncology and is the most natural local candidate for cross-border Casgevy coordination. Sheikh Khalifa Medical City and Tawam Hospital both operate hematology and oncology services of national scale. That said, for adolescent hemoglobinopathy cases specifically, King Faisal Specialist Hospital and Research Centre (KFSH and RC) in Riyadh has a longer track record with sickle cell and beta-thalassemia transplant programs than any UAE institution, and KSA holds an established SFDA approval for Casgevy. Many UAE families with a child or adolescent candidate end up choosing between local capability that is still building and a regional referral to KSA where the path is more worn.

The EDE named-patient pathway applied to Casgevy

The federal pathway for a UAE-licensed physician to obtain a medicine that is not registered or not stocked locally is the unregistered-medicine import permit, administered through the Emirates Drug Establishment (EDE) portal at ede.gov.ae since 29 December 2025, when the EDE took over 44 core services from MOHAP under Federal Decree-Law No. 38 of 2024. The framework allows hospitals and licensed pharmaceutical establishments to import a specific medicine for a specific patient when the medicine is approved by a recognised reference authority such as the US FDA and a locally registered alternative is not suitable.

For Casgevy, the standard application set is not enough on its own. The clinical justification packet expands in three directions specific to gene-edited cell therapy. First, institutional capability sign-off. The dispensing facility must confirm in writing that it holds, or has a defined arrangement to access, busulfan myeloablative conditioning capability, certified cell-therapy infusion infrastructure with cryogenic storage in the liquid nitrogen vapor phase below minus 150 degrees Celsius, and post-infusion inpatient support for the cytopenic window. Second, the treating physician's fertility preservation discussion must be documented, because the busulfan conditioning carries a high risk of permanent infertility and the discussion is mandatory before any patient initiates the pathway. Third, the application typically references the Vertex Authorized Treatment Center qualification framework. Where the UAE-resident patient is going to receive the cells in the UAE, the receiving institution must hold ATC status or a formal arrangement with a qualified center.

A complete EDE application for a Casgevy case typically includes the clinical justification letter from the treating hematologist (diagnosis, genotype confirmation, history of vaso-occlusive crises or transfusion burden, prior therapy failures including hydroxyurea, transfusions, voxelotor, crizanlizumab where applicable, and the case for gene therapy now), the treating physician's MOHAP, DHA, DOH, or Sharjah Health Authority license verification, an anonymised patient identifier, full product details for the manufactured cell product, the destination dispensing facility name with license number and pharmacy in charge, the cryogenic chain-of-custody plan, the fertility preservation record, and a statement of institutional capability or referral arrangement. Approval timelines for routine cases are 5 to 15 business days. Complex first-of-kind submissions extend to 4 to 6 weeks. For a Casgevy case, the EDE submission timeline is rarely the gating item. The institutional capability assembly is.

Where Casgevy gets dispensed in the UAE

Casgevy is a patient-specific manufactured cell product. It is never stocked anywhere. Each manufactured product is patient-specific by definition because it is the patient's own apheresis-collected, CRISPR-edited CD34+ cells. The receiving facility must hold cryogenic vapor-phase liquid nitrogen storage, the apheresis suite that collected the cells (or a documented chain to it), a qualified cell-therapy infusion unit, and a post-conditioning inpatient ward. Within the UAE, the institutional candidates with the closest capability to this profile are Cleveland Clinic Abu Dhabi (adult cell-therapy capability, ASHP-accredited pharmacy, on Al Maryah Island), Sheikh Khalifa Medical City in Abu Dhabi (586-bed JCI-accredited acute-care hospital in the SEHA network managed by the Cleveland Clinic), and Tawam Hospital in Al Ain (national referral center for oncology with a cancer center developed in collaboration with the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center). American Hospital Dubai, as a Mayo Clinic Care Network member, also holds advanced pediatric and adult oncology services.

For pediatric and adolescent Casgevy cases, the practical reality is that very few institutions anywhere combine the full toolset for adolescent gene-therapy delivery in a way that has been routinely exercised. Many UAE families coordinate referral to KFSH and RC in Riyadh, where the SFDA holds an established Casgevy approval and where sickle cell and thalassemia transplant volume is high. Reserve Meds does not select the dispensing facility on the patient's behalf. We document the candidate institutions, the standing capability questions to ask, and we connect the family's treating physician with the UAE or KSA institution's intake team.

Real cost picture for Casgevy in the UAE

The US wholesale acquisition cost for the Casgevy manufactured cell product is approximately USD 2.2 million per patient for the single one-time infusion. The figure is the cell product only. It does not include apheresis cycles, plerixafor-based mobilization, manufacturing logistics, busulfan myeloablative conditioning, the inpatient stay for conditioning and engraftment, transfusion support during cytopenia, fertility preservation, the long-term follow-up registry, or international travel. In AED at the 3.67 peg, the cell product alone is approximately AED 8.1 million.

All-in delivered cost for a UAE family pursuing Casgevy cross-border is materially higher than the cell-product list price. International logistics for the apheresis material out and the edited cell product back are not standard biologic shipments. The patient typically travels to the treating ATC rather than the cell product traveling alone. Travel, accommodation for a multi-month treatment course, and caregiver support stack on top of the institutional bill. Insurance in the UAE handles named-patient gene therapy case by case. Thiqa, administered by Daman for UAE nationals in Abu Dhabi, has the broadest specialty coverage of the Emirati insurers. Daman, GIG Gulf, Sukoon, ADNIC, and Orient each assess gene-therapy cases on individual review and most require pre-authorisation. We supply the documentation set that lets your insurer assess the case. We do not promise coverage from any insurer.

Typical timeline for Casgevy in the UAE

The EDE permit itself is not the long pole. Routine EDE submissions process in 5 to 15 business days; complex first-of-kind submissions extend to 4 to 6 weeks. The Casgevy pathway from referral to first day post-infusion is typically several months and can extend to a year. Eligibility workup including bone marrow assessment, infection screen, organ function evaluation, and the mandatory fertility preservation discussion is the first window. Plerixafor-based mobilization and apheresis follow, and may require multiple cycles to reach the target CD34+ cell yield. Manufacturing turnaround at the Vertex facility is several weeks. Inpatient busulfan conditioning is comparable to a stem-cell transplant admission. Profound cytopenia and engraftment monitoring extend several weeks more. Long-term follow-up through the Vertex post-marketing registry extends multiple years. Reserve Meds frames the case as a multi-month engagement, not a permit-and-ship cycle.

What your physician needs to provide

The clinical justification letter for a Casgevy EDE submission carries more weight than the average named-patient letter because the therapy is novel, the conditioning regimen is high-intensity, and the institutional capability assertion is part of the submission. The treating hematologist's letter typically addresses the patient's diagnosis and genotype (HbSS or compound heterozygous SCD, beta-thalassemia genotype with transfusion dependence), the documented history of vaso-occlusive events or red cell transfusion burden, prior therapy outcomes including hydroxyurea response, voxelotor and crizanlizumab trial where applicable, transfusion-related iron overload, and the rationale for one-time gene-edited cell therapy now rather than ongoing chronic management or matched-sibling allogeneic stem cell transplant. The minimum target dose is 3 x 10^6 CD34+ cells per kilogram, and the letter typically includes the weight-based dose calculation and the planned conditioning regimen reference.

Three documents sit alongside the letter. The fertility preservation discussion record is mandatory. The institutional capability or referral arrangement statement is the substantive override for gene therapy cases. The patient and family informed consent for a multi-month inpatient and outpatient course is documented before the EDE submission goes in. The treating physician's license must be in active standing in the emirate of the dispensing facility (MOHAP for the Northern Emirates, DHA for Dubai, DOH for Abu Dhabi and Al Ain, Sharjah Health Authority for Sharjah).

Common questions about Casgevy in the UAE

Will Daman, Thiqa, GIG Gulf, Sukoon, ADNIC, or Orient cover this? Each insurer assesses gene-therapy cases case by case. Thiqa, the government-funded programme for UAE nationals administered by Daman, has the broadest specialty coverage in Abu Dhabi. Pre-authorisation is the norm. We do not promise coverage from any insurer. We supply the documentation set that lets your insurer assess the case.

Will my DOH-licensed or DHA-licensed physician's letter be sufficient? Yes. Any UAE-licensed hematologist practicing in good standing in the emirate of the dispensing facility has signing authority on the clinical justification letter. If the dispensing facility is in Abu Dhabi, a DOH-licensed hematologist is the natural fit. If the case is referred to KSA, a KSA-licensed treating physician at the receiving institution coordinates with the UAE physician.

Is Casgevy a controlled substance? No. Casgevy is not a DEA scheduled substance. The federal narcotics framework does not apply. The cryogenic chain-of-custody documentation does, and the dispensing facility's pharmaceutical establishment licence is verified at the EDE step.

Why Casgevy and not Lyfgenia? Lyfgenia (lovotibeglogene autotemcel, bluebird bio) is approved by the FDA for sickle cell disease but carries a boxed warning for hematologic malignancy and is not registered in the UAE or KSA. Casgevy holds broader international approval (UK MHRA, EMA, SFDA, Health Canada) and uses a CRISPR-Cas9 BCL11A enhancer edit to reactivate fetal hemoglobin rather than a lentiviral gene addition. The clinical choice rests with the treating cell-therapy team and the family. Reserve Meds does not steer the clinical decision.

What about fertility? The busulfan myeloablative conditioning carries a high risk of permanent infertility. Fertility preservation discussion is mandatory before any patient initiates the pathway. For adolescents, the discussion typically involves the patient, the family, and a fertility preservation specialist before the apheresis stage begins.

Will Casgevy be available locally in the UAE? The Emirates Drug Establishment continues to expand its advanced therapy pathway, and the UAE specialty hospital network is investing in cell-therapy infrastructure. We expect the local pathway to mature year over year. As of this page's review date, regional Casgevy capability is more established at KFSH and RC in KSA than at any single UAE institution, and many families coordinate accordingly.

Where Reserve Meds fits in Casgevy cases

Reserve Meds is a US-based concierge coordinator. We do not replace your treating hematologist, the EDE, the dispensing pharmacy, or the qualified treating institution. For a Casgevy case specifically, our work is not a "ship a drug" engagement. It is a treating-center introduction, an institutional capability documentation engagement, and a patient-travel coordination engagement. We identify the relevant approved jurisdiction for the family's circumstances (UAE locally where capability supports it, KSA regionally where it does not). We document the institutional capability questions the family's physician should ask. We assemble the regulatory documentation kit. We hold one named coordinator through the multi-month case. No prior Reserve Meds case experience for Casgevy as of this review date; the operating playbook is documented and the working unit is the family plus the treating physician plus the receiving institution. Reserved for you.

Next step

If a treating hematologist in the UAE is weighing Casgevy for a family member, the waitlist is the first step. We respond within 24 to 48 hours with an eligibility confirmation and a documentation kit for the physician.

Join the Casgevy waitlist

Reserved for you.

Related

• Casgevy clinical resource
• Casgevy in Qatar
• Casgevy in Kuwait
• Lyfgenia in the UAE
• United Arab Emirates country page

Sources

1. FDA approval, Casgevy (exagamglogene autotemcel), Vertex Pharmaceuticals, BLA approval December 2023 for SCD and January 2024 for TDT.
2. UAE Ministry of Health and Prevention, Issue of Permit to Import Medicines for Personal Use; UAE Federal Decree-Law No. 38 of 2024 and the Emirates Drug Establishment portal at ede.gov.ae.
3. Vertex Pharmaceuticals US launch disclosure, Casgevy list price of approximately USD 2.2 million per single infusion (December 2023).